Christophe Glorieux
State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Corrigendum to "Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling" [Redox Biol. 38, (2021), 101780].
Journal: Redox biology
Published: August 28, 2026
Ascorbate-driven quinone redox cycling as a pro-oxidant anticancer strategy.
Journal: Redox biology
Published: March 19, 2026
Mitochondrial metabolism as a pharmacological target for cancer therapeutics.
Journal: Pharmacological reviews
Published: June 04, 2025
The complex interplay between redox dysregulation and mTOR signaling pathway in cancer: A rationale for cancer treatment.
Journal: Biochemical pharmacology
Published: October 21, 2024
Targeting ROS in cancer: rationale and strategies.
Journal: Nature reviews. Drug discovery
Published: May 15, 2024
Calorimetric evidence for the existence of an intermediate phase between the ferroelectric nematic phase and the nematic phase in the liquid crystal RM734.
Journal: Physical review. E
Published: February 21, 2024
The Multifaceted Roles of NRF2 in Cancer: Friend or Foe?
Journal: Antioxidants (Basel, Switzerland)
Published: December 06, 2023
Phase transitions study of the liquid crystal DIO with a ferroelectric nematic, a nematic, and an intermediate phase and of mixtures with the ferroelectric nematic compound RM734 by adiabatic scanning calorimetry.
Journal: Physical review. E
Published: October 18, 2022
PLA2G2A Phospholipase Promotes Fatty Acid Synthesis and Energy Metabolism in Pancreatic Cancer Cells with K-ras Mutation.
Journal: International journal of molecular sciences
Published: July 31, 2022
Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.
Journal: JAMA network open
Published: December 13, 2021
Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
Journal: Journal of hematology & oncology
Published: December 08, 2021
Last Updated: 09/26/2026